Review: Cooperative group trials — Southwest Oncology Group (SWOG) innovations in advanced prostate cancer

Therapeutic Advances in Medical Oncology

Volumn 1, Issue 2, 2009, Pages 69-77

  Dorff, Tanya B ^a   Quinn, David I ^a   Tangen, Cathy M ^b   Crawford, E David ^c   Petrylak, Daniel P ^d   Higano, Celestia S ^e   Raghavan, Derek ^f   Vogelzang, Nicholas J ^g   Hussain, Maha H A ⁱ  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b SOUTHWEST ONCOLOGY GROUP STATISTICAL CENTER   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d Och Spine at New York Presbyterian Hospitals   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f TAUSSIG CANCER INSTITUTE   (United States)

^g NEVADA CANCER INSTITUTE   (United States)

^h UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

ⁱ UNIVERSITY OF MICHIGAN   (United States)

Author keywords

advanced prostate cancer; androgen deprivation; chemotherapy; clinical trials

Indexed keywords

ANDROGEN; ATRASENTAN; BICALUTAMIDE; DOCETAXEL; ESTRAMUSTINE; ETOPOSIDE; FLUTAMIDE; GONADORELIN; INTERLEUKIN 6; ISPINESIB; IXABEPILONE; MITOXANTRONE; NILUTAMIDE; OSTEOCLAST DIFFERENTIATION FACTOR; PREDNISONE; ZOLEDRONIC ACID;

ADVANCED CANCER; ANDROGEN DEPRIVATION THERAPY; BODY MASS; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CASTRATION; HORMONE SENSITIVITY; HUMAN; MICROENVIRONMENT; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; REVIEW; TREATMENT RESPONSE;

EID: 77953443633     PISSN: 17588340     EISSN: None     Source Type: Journal    
DOI: 10.1177/1758834009343454     Document Type: Review

References (57)

1. Banerjee, S., Hussain, M., Wang, Z., Saliganan, A., Che, M., Bonfil, D. et al. (2007) In vitro and in vivo molecular evidence for better therapeutic efficacy of ABT-627 and taxotere combination in prostate cancer. Cancer Res 67: 3818-26.
2. Beer, T.M., Goldman, B., Synold, T.W., Ryan, C.W., Vasist, L.S., VanVeldheusin Jr, P.J. et al. (2008) Southwest oncology group phase II study of ispenesib in androgen-independent prostate cancer previously treated with taxanes. Clin Genitourin Cancer 6: 103-9.
3. Beer, T.M., Tangen, C.M., Bland, L.B., Hussain, M., Goldman, B.H., deLoughery, T.G. et al. (2006) The prognostic value of hemoglobin change after initiating androgen-deprivation therapy for newly diagnosed metastatic prostate cancer. Cancer 107: 489-96.
4. Berruti, A., Fara, E., Tucci, M., Tarabuzzi, R., Mosca, A., Terrone, C. et al. (2005) Oral estramustine plus oral etoposide in the treatment of hormone refractory prostate cancer patients: a phase II study with a 5-year follow-up. Urol Oncol 23: 1-7.
5. Berry, D.L., Moinpour, C.M., Jiang, C.S., Ankerst, D.P., Petrylak, D.P., Vinson, L.V. et al. (2008) Quality of life and pain in advanced stage prostate cancer: results of a southwest oncology group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone. J Clin Oncol 24: 2828-35.
6. Bhandari, M.S., Crook, J. and Hussain, M. ( 2005) Should intermittent androgen deprivation be used in routine clinical practice? J Clin Oncol 32: 8212-18.
7. Bruchovsky, N., Rennie, P.S., Coldman, A.J., Goldenberg, S.L., To, M. and Lawson, D. ( 1990) Effects of androgen withdrawl on the stem cell composition of the Shionogi carcinoma. Cancer Res 50: 2275-83.
8. Caldiroli, M., Cova, V., Lovisolo, J.A., Reali, L. and Bono, A.V. ( 2001) Antiandrogen withdrawl in the treatment of hormone-relapsed prostate cancer: single institutional experience. Eur Urol 39: 6-10.
9. Carducci, M.A., Padley, R.J., Breul, J., Vogelzang, N.J., Zonnenberg, B.A., Daliani, D.D. et al. (2003) Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol 21: 679-89.
10. Carducci, M.A., Saad, F., Abrahamsson, P.A., Dearnaley, D.P., Schulman, C.C., North, S.A. et al. (2007) A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer 110: 1959-66.
11. Chung, L.W.K., Baseman, A., Assikis, V. and Zhau, H.E. ( 2005) Molecular insights into prostate cancer progression: the missing link of tumor microenvironment. J Urol 173: 10-20.
12. Chung, T.D.K., Yu, J.J., Spiotto, M.T., Bartkowski, M. and Simons, J.W. ( 1999) Characterization of the role of IL-6 in the progression of prostate cancer. Prostate 38: 199-207.
13. Crawford, E.D., Eisenberger, M.A., McLeod, D.G., Spaulding, J.T., Benson, R., Dorr, F.A. et al. (1989) A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. New Engl J Med 321: 419-24.
14. de Bono, J.S., Scher, H.I., Montgomery, R.B., Parker, C., Miller, M.C., Tissing, H. et al. (2008) Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 14: 6302-09.
15. Del Bufalo, D., Di Castro, V., Biroccio, A., Salani, D., Rosano, L., Trisciuoglio, D. et al. (2002) Endothelin-1 protects ovarian cancer cells against paclitaxel-induced apoptosis: requirement for akt activation. Mol Pharmacol 61: 524-32.
16. Dimopoulos, M.A., Panopoulos, C., Bamia, C., Deliveliotis, C., Alivizatos, G., Pantazopoulos, Z. et al. (1997) Oral estramustine and oral etoposide for hormone-refractory prostate cancer. Urology 50: 754-8.
17. Eigl, B.J., Eggener, S.E., Baybik, J., Ettinger, S., Chi, K.N., Nelson, C. et al. (2005) Timing is everything: preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cacner. Clin Cancer Res 11: 4905.
18. Eisenberger, M.A., Blumenstein, B.A., Crawford, E.D., Miller, G., McLeod, D.G., Loehrer, P.J. et al. (1998) Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. New Engl J Med 339: 1036-42.
19. Feldman, B.J. and Feldman, D. ( 2001) The development of androgen-independent prostate cancer. Nat Rev Cancer 1: 34-45.
20. Geller, J., Albert, J., Loza, D., Geller, S. and Stoeltzing, W. ( 1978) DHT concentrations in human prostate cancer tissue. J Clin Endocrinol Metab 46: 440-4.
21. Goh, B.C., Lee, S.C., Wang, L.Z., Fan, L., Guo, J.Y., Lamba, J. et al. (2002) Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. J Clin Oncol 20: 3683-90.
22. Grossman, M.E., Huang, H. and Tindall, D.J. ( 2001) Androgen receptor signaling in androgen-refractory prostate cancer. J Natl Cancer Inst 93: 1687-97.
23. Huan, S.D., Gerridzen, R.G., Yau, J.C. and Stewart, D.J. ( 1997) Antiandrogen withdrawal syndrome with nilutamide. Urology 49: 632-4.
24. Huggins, C. ( 1942) Effect of orchiectomy and irradiation on cancer of the prostate. Ann Surg 115: 1192-200.
25. Hussain, M., Tangen, C.M., Lara, P.N., Vaishampayan, U.N., Petrylak, D.P., Colevas, A.D. et al. (2005) Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naïve patients with hormone-refractory prostate cancer: a southwest oncology group trial S0111. J Clin Oncol 23: 8724-9.
26. Hussain, M., Tangen, C.M., Higano, C., Schellhammer, P.F., Faulkner, J., Crawford, E.D. et al. (2006) Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol 24: 3984-90.
27. Hussain, M., Goldman, B., Tangen, C., Higano, C.S., Petrylak, D.P., Wilding, G. et al. (2009) Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from southwest oncology group trials 9346 (intergroup study 0162) and 9916. J Clin Oncol 27: 2450-2456.
28. Isaacs, J.T. and Coffey, D.S. ( 1991) Adaptation versus selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation therapy as studied in the Dunning R-3327-H adenocarcinoma. Cancer Res 41: 5070-5.
29. Jemal, A., Siegel, R., Ward, E., Murray, T., Hao, Y. et al. (2009) Cancer statistics. CA Cancer J Clin 57: 225-249.
30. Kantoff, P.W., Halabi, S., Conaway, M., Picus, J., Kirshner, J., Hars, V. et al. (1999) Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol 17: 2506-13.
31. Keuppens, F., Whelan, P., Carneiro de Moura, J.L., Newling, D., Bono, A., Denis, L. et al. (1993) Orchidectomy versus goserelin plus flutamide in patients with metastatic prostate cancer (EORTC 30853). European Organization for Research and Treatment of Cancer - Genitourinary Group. Cancer 72: 3863-9.
32. Labrie, F., Dupont, A., Belanger, A., Giguere, M., Lacoursiere, Y., Emond, J. et al. (1985) Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in advanced prostate cancer: a marked improvement in survival. J Steroid Biochem Mol Biol 23: 833-41.
33. Logothetis, C.J., Samuels, M.L., von Eschenbach, A.C., Trindade, A., Ogden, S., Grant, C. et al. (1983) Doxorubicin, mitomycin-C, and 5-fluorouracil (DMF) in the treatment of metastatic hormonal refractory adenocarcinoma of the prostate with a note on the staging of metastatic prostate cancer. J Clin Oncol 1: 368-79.
34. Montgomery, R.B., Goldman, B., Tangen, C.M., Hussain, M., Petrylak, D.P., Page, S. et al. (2007) Association of body mass index with response and survival in men with metastatic prostate cancer: southwest oncology group trials 8894 and 9916. J Urol 178: 1946-51.
35. Mostaghel, E.A., Page, S.T., Lin, D.W., Fazli, L., Coleman, I.M., True, L.D. et al. (2007) Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res 67: 5033-41.
36. Mukamel, E., Nissenkorn, I. and Servadio, C. ( 1980) Early combined hormonal and chemotherapy for metastatic carcinoma of prostate. Urology 16: 257-60.
37. Nelson, J.B., Nabulsi, A.A., Vogelzang, N.J., Breul, J., Zonnenberg, B.A., Daliani, D.D. et al. (2003) Suppression of prostate-cancer induced bone remodeling by the endothelin receptor A antagonist atrasentan. J Urol 169: 1143-9.
38. Oakley-Girvan, I., Kolonel, L.N., Gallagher, R.P., Wu, A.H., Felberg, A. and Whittemore, A.S. ( 2003) Stage at diagnosis and survival in a multi-ethnic cohort of prostate cancer patients. Am J Public Health 93: 1753-9.
39. Osborne, C.K., Blumenstein, B., Crawford, E.D., Coltman Jr, C.A., Smith, A.Y., Lambuth, B.W. et al. (1990) Combined versus sequential chemo-endocrine therapy in advanced prostate cancer: final results of a randomized southwest oncology group study. J Clin Oncol 8: 1675-82.
40. Petrylak, D.P., Ankerst, D.P., Jiang, C.S., Tangen, C.M., Hussain, M.H.A., Lara Jr, P.N. et al. (2006) Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst 98: 516-21.
41. Petrylak, D.P., Tangen, C.M., Hussain, M.H., Lara Jr, P.N., Jones, J.A., Taplin, M.E. et al. (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone in advanced refractory prostate cancer. New Engl J Med 351: 1513-20.
42. Pienta, K.J., Fisher, E.I., Eisenberger, M.A., Mills, G.M., Goodwin, J.W., Jones, J.A. et al. (2001) A phase II trial of estramustine and etoposide in hormone refractory prostate cancer: a southwest oncology group trial (SWOG 9407). Prostate 46: 257-61.
43. Pienta, K.J., Redman, B.G., Bandekar, R., Strawderman, M., Cease, K., Esper, P.S. et al. (1997) A phase II trial of oral estramustine and oral etoposide in hormone-refractory prostate cancer. Urology 50: 401-7.
44. Pinski, J. and Dorff, T.B. ( 2005) Prostate cancer metastases to bone: pathophysiology, pain management, and the promise of targeted therapy. Eur J Cancer 41: 932-40.
45. Rosano, L., Spinella, F., Salani, D., Natali, P.G. and Bagnato, A. ( 2003) Therapeutic targeting of the endothelin a receptor in human ovarian carcinoma. Cancer Res 63: 2447-53.
46. Sartor, A.O., Tangen, C.M., Hussain, M.H.A., Eisenberger, M.A., Parab, M., Fontana, J.A. et al. (2008) Antiandrogen withdrawl in castrate-refractory prostate cancer. Cancer 112: 2393-400.
47. Savarese, D.M., Halabi, S., Hars, V., Akerley, W.L., Taplin, M.E., Godley, P.A. et al. (2001) Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B. J Clin Oncol 19: 2509-16.
48. Schellhammer, P.F., Venner, P., Haas, G.P., Small, E.J., Nieh, P.T., Seabaugh, D.R. et al. (1997) Prostate specific antigen decreases after withdrawl of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade. J Urol 157: 1731-5.
49. Small, E.J. and Srinivas, S. ( 1995) The antiandrogen withdrawl syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer. Cancer 76: 1428-34.
50. Smith, D.C., Esper, P., Strawderman, M., Redman, B. and Pienta, K.J. ( 1999) Phase I trial of estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer. J Clin Oncol 17: 1664-71.
51. Smith, P.C. and Keller, E.T. ( 2001) Anti-interleukin-6 monoclonal antibody induces regression of human prostate cancer xenografts in nude mice. Prostate 48: 47-53.
52. Sumiyoshi, Y., Hashino, K., Nakatsuzi, H., Yamashita, Y. and Karashima, T. ( 2000) Oral estramustine phosphate and oral etoposide for the treatment of hormnone-refractory prostate cancer. Int J Urol 7: 243-7.
53. Sweeney, C.J. ( 2006) ECOG: CHAARTED - chemohormonal therapy versus androgen ablation randomized trial for extensive disease in prostate cancer. Clin Adv Hematol Oncol 4: 588-90.
54. Tannock, I.F., Osoba, D., Stockler, M.R., Ernst, D.S., Neville, A.J., Moore, M.J. et al. (1996) Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 14: 1756-64.
55. Tannock, I.F., deWit, R., Berry, W.R., Horti, J., Pluzanska, A., Chi, K.N. et al. (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. New Engl J Med 351: 1502-12.
56. Torti, F.M., Aston, D., Lum, B.L., Kohler, M., Williams, R., Spaulding, J.T. et al. (1983) Weekly doxorubicin in endocrine-refractory carcinoma of the prostate. J Clin Oncol 1: 477-82.
57. Tyrrell, C.J., Altwein, J.E., Klippel, F., Varenhorst, E., Lunglmayr, G., Boccardo, F. et al. (1993) Multicenter randomized trial comparing zoladex with zoladex plus flutamide in the treatment of advanced prostate cancer. Survival update. The International Prostate Cancer Study Group. Cancer 72: 3878-9.